Molecular Biosystems Acquisition Builds Alliance's Cardiac Imaging Portfolio
This article was originally published in The Gray Sheet
Executive Summary
Alliance Pharmaceutical's acquisition of Molecular Biosystems, Inc. for $10.2 mil. in stock will expand its existing ultrasound cardiac imaging agent portfolio to include royalties for Optison.